چكيده به لاتين
Smart nanocarriers with stimuli-responsive behavior are considered promising platforms for various drug delivery applications. Drug carriers to treat the tumor microenvironment need criteria to increase drug delivery efficiency. Considering the special conditions of cancer cells, such as acidic pH, pH-sensitive nanocarriers were used for drug release. In this study, chitosan-graphene-oxide nanocarriers were synthesized and used for encapsulating the drugs doxorubicin (Adriamycin) and Herceptin (Trastuzumab) as general anticancer drugs.
Various analytical methods (for example, SEM, RAMAN, AFM, TGA, XRD, and FT-IR) were used to describe the structure and properties of the fabricated nanocarriers.
Fitting the release data with four models including zero-order, first-order, Higuchi, and Kors-Meier-Peppas models showed that the addition of GO changed the drug release mechanism and allowed uniform release compared to pure chitosan nanocarriers, which were rate const. E increased and finally, due to the presence of GO sheets and more drug loading between the sheets, the drug release also increased compared to pure chitosan. The release of the combination of two drugs at pH=5.5 from chitosan-graphene oxide nanocarriers was 88% in 4 days, while chitosan carriers released only 67% of the drug in 4 days. Finally, the cytotoxicity of the synthesized carriers was evaluated on SK-BR-3 and MCF-7 cell lines. Chitosan-graphene oxide nanocarriers at pH = 5.5 showed 19% survival on SK-BR-3, which is a HER-2 positive cell line, for 72 hours. The synthesized nanocarriers have improved mechanical properties and better drug delivery performance than chitosan carriers, providing controlled and targeted intracellular drug delivery, which is expected to be a promising new therapy for the treatment of overexpressing breast cancer cells by HER-2.
